The healing effect of rebamipide for artificial ulcer after treatment of endoscopic submucosal dissection: a prospective randomized trial

The healing effect of rebamipide for artificial ulcer after treatment of endoscopic submucosal dissection: a prospective randomized trial - Rebamipide treatment after ESD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001740

Enrollment

100

Registered

2009-02-27

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer, Gastric adenoma

Interventions

Administration of PPI(proton pump inhibitor) plus rebamipide 300mg for 8weeks Administration of PPI for 8weeks after ESD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients of adenocarcinoma and early gastric cancer who receive ESD.

Exclusion criteria

Exclusion criteria: The patients who: (1)repeat hematemesis, (2) pregnant, (3)has sever liver, renal and cardiopulumonary disease, (4)has allergic drug reaction.

Design outcomes

Primary

Measure	Time frame
The healing ratio of artificial ulcer at 4weeks after ESD.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026